TW200512293A - Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics - Google Patents

Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics

Info

Publication number
TW200512293A
TW200512293A TW093116334A TW93116334A TW200512293A TW 200512293 A TW200512293 A TW 200512293A TW 093116334 A TW093116334 A TW 093116334A TW 93116334 A TW93116334 A TW 93116334A TW 200512293 A TW200512293 A TW 200512293A
Authority
TW
Taiwan
Prior art keywords
eif
apoptosis
sirnas
specific
inhibition
Prior art date
Application number
TW093116334A
Other languages
English (en)
Chinese (zh)
Inventor
John E Thompson
Catherine Taylor
Original Assignee
Senesco Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies Inc filed Critical Senesco Technologies Inc
Publication of TW200512293A publication Critical patent/TW200512293A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW093116334A 2003-06-06 2004-06-07 Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics TW200512293A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47619403P 2003-06-06 2003-06-06
US50473103P 2003-09-22 2003-09-22
US52824903P 2003-12-10 2003-12-10
US55767104P 2004-03-31 2004-03-31
US57581404P 2004-06-02 2004-06-02

Publications (1)

Publication Number Publication Date
TW200512293A true TW200512293A (en) 2005-04-01

Family

ID=34084831

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093116334A TW200512293A (en) 2003-06-06 2004-06-07 Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics

Country Status (9)

Country Link
EP (1) EP1636364A2 (de)
JP (1) JP5666074B2 (de)
KR (1) KR20060013428A (de)
AU (1) AU2004258070B2 (de)
CA (1) CA2528372A1 (de)
IL (1) IL172365A0 (de)
NZ (2) NZ574973A (de)
TW (1) TW200512293A (de)
WO (1) WO2005007853A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381708B2 (en) 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
NZ542665A (en) 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US20140371299A1 (en) * 2004-06-07 2014-12-18 Senesco Technologies, Inc. Use of Apoptosis-Specific elF-5A siRNA to Down Regulate Expression of Proinflammatory Cytokines to Treat Sepsis
CN101027393A (zh) * 2004-07-20 2007-08-29 森尼斯科技术公司 凋亡特异性elF－5AsiRNA和反义多核苷酸在抑制/阻抑炎症反应中的用途
EP1959010A3 (de) * 2004-12-03 2009-02-25 Senesco Technologies, Inc. Apoptosespezifisches eIF-5A und Polynukleotide zu seiner Kodierung
AR057234A1 (es) * 2005-12-13 2007-11-21 Senesco Technologies Inc Uso de eif-5a para destruir celulas de meiloma multiple
KR20080082688A (ko) * 2006-03-20 2008-09-11 세네스코 테크놀로지스 인코포레이티드 공여자의 섬 세포 채취 과정 동안에 섬 세포를아폽토시스로부터 보호하는 신규 방법
CA2634814A1 (en) * 2006-03-20 2007-09-27 Senesco Technologies, Inc. Use of apoptosis-specific eif-5a sirna to down regulate expression of proinflammatory cytokines to treat sepsis
AU2007226878A1 (en) * 2006-03-20 2007-09-27 Senesco Technologies, Inc. A novel method of protecting islet cells from apoptosis during the donor harvesting process
WO2007115047A2 (en) * 2006-03-29 2007-10-11 Senesco Technologies, Inc. Inhibition of hiv replication and expression of p24 with eif-5a
KR20100046266A (ko) * 2007-08-20 2010-05-06 세네스코 테크놀로지스 인코포레이티드 섬 세포의 기능을 보존하고 아폽토시스를 방지하는 ｅＩＦ-5Ａ1 ｓｉＲＮＡ의 용도
WO2009114487A2 (en) 2008-03-07 2009-09-17 Senesco Technologies, Inc. Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a desired polynucleotide
WO2009144933A1 (ja) * 2008-05-27 2009-12-03 国立大学法人東京大学 アポトーシス誘導薬
US8445638B2 (en) 2008-09-03 2013-05-21 Senesco Technologies, Inc. Use of a truncated eIF-5A1 polynucleotide to induce apoptosis in cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980702160A (ko) * 1995-02-13 1998-07-15 하우스 한스 루돌프. 나톨리 안토니오 진핵생물 개시 인자 5에이(이아이에프-5에이) 돌연변이체
JP2005500025A (ja) * 2001-05-29 2005-01-06 サーナ・セラピューティクス・インコーポレイテッド 女性生殖疾病及び状態の核酸に基づく調節
US7968523B2 (en) * 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
US7381708B2 (en) * 2001-07-23 2008-06-03 Sensco Technologies, Inc. Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
WO2003010180A1 (en) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US7166467B2 (en) * 2001-07-23 2007-01-23 Senesco Technologies, Inc. Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
NZ542665A (en) * 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1

Also Published As

Publication number Publication date
NZ544159A (en) 2009-04-30
AU2004258070A1 (en) 2005-01-27
KR20060013428A (ko) 2006-02-09
EP1636364A2 (de) 2006-03-22
IL172365A0 (en) 2006-04-10
NZ574973A (en) 2010-10-29
JP5666074B2 (ja) 2015-02-12
AU2004258070B2 (en) 2008-12-11
CA2528372A1 (en) 2005-01-27
WO2005007853A3 (en) 2005-10-27
JP2006526989A (ja) 2006-11-30
WO2005007853A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2004078940A8 (en) USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
WO2005007853A3 (en) Inhibition of apoptosis-specific elf-5a (“eif-5a1”) with antisense oligonucleotides and sirnas as anti-inflammatory therapeutics
DK1230375T3 (da) Inhibering af genekspression med dsRNA
WO2003012052A3 (en) Specific inhibition of gene expression by small double stranded rnas
WO2007005645A3 (en) Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
EP1537227A4 (de) VERFAHREN ZUR WIRKSAMEN RNA-INTERFERENZ IN SûUGERZELLEN
EP2527444A3 (de) Antisense-Oligonukleotid-Modulation einer STAT3-Expression
WO2008078180A3 (en) Materials and methods for the generation of transcripts comprising modified nucleotides
WO2004035803A3 (en) Method and nucleic acids for the treatment of breast cell proliferative disorders
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
DK0731835T3 (da) Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
WO2005118824A8 (en) Methods and compositions for the inhibition of gene expression
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
EP1176965A4 (de) Antisensmodulierung des fas-vermittelten signalwegs
EP1509251A4 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
NZ604094A (en) Double stranded rna compounds to rhoa and use thereof
IL159966A0 (en) Nucleic acids, polypeptides, and methods for modulating apoptosis
NO960965D0 (no) Genet Grb3-3 med varianter derav samt deres anvendelse
WO2004016215A3 (en) Use of antisense oligonucleotides to inhibit the expression of akt-1
TW200615001A (en) Use of apoptosis-specific eIF-5A siRNAs and antisense polynucleotides to inhibit/suppress an inflammatory response
ATE555201T1 (de) Verwendung von sirna zur abschaffung der expression von eif-5a1 in der behandlung von glaukoma
WO2007109674A3 (en) Use of eif-5a1 sirna and antisense to treat sepsis or haemorrhagic shock
ATE396262T1 (de) Rna polymerase i transkriptionsfaktor tif-ia
AU3649802A (en) Dna encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5a, transgenic plants and method for controlling senescence programmed and cell death in plants